Page results
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
This page tells you about the procedure known as a renal cryoablation. It explains what is involved and what the possible risks are.
-
Acute lymphoblastic leukaemia (ALL) is a form of cancer that affects the cells in the bone marrow, the soft material inside your bones.
-
Information on contrast agents for X-ray, fluoroscopy, CT and angiography examinations at NHNN
-
What to expect from your neuro-oncology Clinical Nurse Specialist (key worker) at the NHNN
-
Your acute myeloid leukaemia (AML) treatment will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Preterm infants do not get used to repeated pain in the way that full-term infants, children and adults do habituate to pain, finds a study at UCLH and UCL.
-
A major new consortium led by UCLH and UCL has been awarded £6.8 million by the National Institute of Health Research to conduct the largest clinical study of long COVID over the next two years.
-
Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.
-
The children and young people's division at UCLH are running two events for young people aged 13 - 24 years.
File results
-
FOI/2023/0429 - Breast cancer treatment/ systemic anti-cancer therapies
-
FOI/2023/0426 - Maternity services staffing levels
-
FOI/2023/0422 - Renal cell treatment for carcinoma and melanoma
-
FOI/2023/0416 - Treatments for non-small cell lung cancer
-
FOI/2023/0415 - Contact details for senior staff at Estates and Facilities
-
FOI/2023/0414 - Operation cancelled for non-clinical reasons - 2018-2022
-
FOI/2023/0413 - Care hotels for patients used/ booked by Trust - 2022/23
-
FOI/2023/0410 - Clinical systems at the Trust
-
FOI/2023/0403 - Patients detained under the Mental Health Act - 2018-2023
-
FOI/2023/0326 - Risk management system reporting rates for adverse events